Pyrotinib Combined With Trastuzumab And Chemotherapy in HER2-positive MBC
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- HER2 Positive Breast Cancer
- Metastatic Breast Cancer
- Type
- Observational
- Design
- Observational Model: CohortTime Perspective: Retrospective
Participation Requirements
- Age
- Between 18 years and 70 years
- Gender
- Only males
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT04609540
- Collaborators
- Not Provided
- Investigators
- Not Provided
Get Well Soon